利瓦罗克萨班和达比加特兰通过前激素复杂度的逆转:一项随机的,安慰剂控制的,在健康受试者身上进行的交叉研究
Elise S Eerenberg1, Pieter W Kamphuisen, Meertien K Sijpkens
1Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands. e.s.eerenberg@amc.uva.nl
Circulation
|September 9, 2011
概括
复合蛋白缩剂 (PCC) 有效地逆转了里瓦洛克萨班的作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 里瓦罗克萨班和达比加特兰是用于预防和治疗血栓栓塞的新型口服抗凝药.
- 一个关键的局限性是缺乏易于获得的解毒剂,用于紧急出血.
- 正在研究作为一种潜在的逆转剂的前素复合缩物 (PCC).
研究的目的:
- 评估PCC在逆转里瓦罗克萨班和达比加特兰抗凝剂作用中的有效性.
- 评估PCC对健康志愿者的特定凝血参数的影响.
主要方法:
- 一项随机,双盲,安慰剂控制的研究,涉及12名健康的男性志愿者.
- 参与者接受了里瓦罗克萨班或达比加特兰,随后给予PCC或盐水.
- 在药物和PCC/盐水注射之前和之后进行了凝血测试.
主要成果:
- PCC完全和立即逆转了里瓦洛克萨班诱导的前热血素时间延长和正常化的内源性血栓潜力.
- 盐水对利瓦洛克萨班的抗凝活性没有影响.
- PCC没有恢复受达比加特兰影响的凝血测试,包括aPTT,ECT和TT.
结论:
- 在健康人群中,PCC有效地和快速地逆转了里瓦洛克萨班的抗凝固作用.
- PCC在测试剂量下没有显示出对逆转达比加特兰抗凝剂作用的显著影响.
- 可能需要进一步的研究来确定达比加特兰的有效逆转剂.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

